BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

5:29 PM
 | 
Oct 24, 2012
 |  BC Extra  |  Company News

FDA grants ponatinib Priority Review

FDA accepted and granted Priority Review to an NDA from Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) for ponatinib...

Read the full 61 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >